Genomics

Dataset Information

0

RNA sequencing of sputum cells from a phase IIa placebo controlled clinical trial of Risankizumb in severe asthma


ABSTRACT: Interleukin (IL)-23 is implicated in T2 and T17-mediated airway inflammation, supporting a role in asthma. We undertook a Phase II, randomized, double-blind, placebo-controlled, 24-week, parallel-group, multicenter trial to assess the efficacy and safety of risankizumab, an IL23p19 monoclonal antibody, administered subcutaneously (90 mg 4 weekly) in adults with severe asthma. Sputum samples were collected at several timepoints: visit 1B (week -3), visit 2 (week 0 proir to treatment), visit 7 (week 20), visit 8 (week 24, end of treatment), visit 12 (week 40, end of observation). RNA sequencing of sputum cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE167074 | GEO | 2024/02/10

REPOSITORIES: GEO

Similar Datasets

| E-GEOD-46238 | biostudies-arrayexpress
2013-04-20 | GSE46238 | GEO
2019-09-12 | GSE137268 | GEO
2015-10-23 | GSE41863 | GEO
| E-GEOD-45111 | biostudies-arrayexpress
| E-GEOD-41863 | biostudies-arrayexpress
2020-03-04 | GSE146306 | GEO
2020-10-25 | GSE148000 | GEO
2020-10-25 | GSE148004 | GEO
2018-08-09 | GSE112260 | GEO